Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence

Zhang,Sha; Yan,Liang; Cui,Can; Wang,Zhen; Wu,Jianhui; Zhao,Min; Dong,Bin; Guan,Xiaoya; Tian,Xiuyun; Hao,Chunyi

doi:10.3892/or.2020.7635

Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence

Authors:
- Sha Zhang
- Liang Yan
- Can Cui
- Zhen Wang
- Jianhui Wu
- Min Zhao
- Bin Dong
- Xiaoya Guan
- Xiuyun Tian
- Chunyi Hao
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato‑Pancreato‑Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/or.2020.7635
Pages: 565-576
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retroperitoneal liposarcoma (RLPS) is one of the most common types of retroperitoneal sarcomas, and has a high recurrence rate. There is an urgent need to further explore its pathogenesis and develop more effective treatment strategies. The aim of the present study was to identify potential driver genes of RLPS through bioinformatics analysis and molecular biology to elucidate potential targets that are suitable for further analysis for the treatment of RLPS. Differentially expressed genes (DEGs) between liposarcoma and normal fatty (NF) tissues were identified based on microarray data through bioinformatics analysis, and thymidylate synthase (TYMS) was selected from the DEGs, based on high content screening (HCS). TYMS expression was evaluated in RLPS tumor tissues and cell lines. A total of 21 RLPS tissues and 10 NF frozen tissues were used for reverse transcription‑quantitative PCR, and 47 RLPS formalin‑fixed specimens were used for immunohistochemical analysis. The effect of TYMS downregulation on cell proliferation, apoptosis, cell cycle progression, and cell migration and invasion were evaluated using lentivirus‑mediated short hairpin RNA. The underlying mechanisms of TYMS in RLPS were examined by protein microarray and verified by western blotting. A total of 855 DEGs were identified. TYMS knockdown had the most notable effect on the proliferative capacity of RLPS cells according to the HCS results. TYMS mRNA expression levels were higher in RLPS tissues compared with NF tissues (P<0.001). TYMS expression was higher in high‑grade RLPS tissues compared with low‑grade RLPS tissues (P=0.003). The patients with positive TYMS expression had a worse overall survival (OS) and disease‑free survival (DFS) compared with the patients with negative TYMS expression (OS, P=0.024; DFS, P=0.030). The knockdown of TYMS reduced proliferation, promoted apoptosis, facilitated cell cycle progression from G1 to S phase, and reduced cell migration and invasion of RLPS cells. Protein microarray analysis and western blotting showed that the Janus Kinase/Signal transducers and activators of transcription pathway was downregulated following TYMS knockdown. In conclusion, TYMS expression is upregulated in RLPS tissues, and downregulation of TYMS reduces RLPS progression.

View Figures

View References

1	Messiou C, Moskovic E, Vanel D, Morosi C, Benchimol R, Strauss D, Miah A, Douis H, van Houdt W and Bonvalot S: Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol. 43:1191–1198. 2017. View Article : Google Scholar : PubMed/NCBI
2	Vijay A and Ram L: Retroperitoneal liposarcoma: A comprehensive review. Am J Clin Oncol. 38:213–219. 2015. View Article : Google Scholar : PubMed/NCBI
3	Paloyo SR, Ramirez AD, David-Paloyo FP and Dofitas RB: Wide excision of a retroperitoneal liposarcoma with en bloc ureterectomy and renal salvage by autotransplantation. Case Rep Transplant. 2019:97251692019.PubMed/NCBI
4	Bagaria SP, Gabriel E and Mann GN: Multiply recurrent retroperitoneal liposarcoma. J Surg Oncol. 117:62–68. 2018. View Article : Google Scholar : PubMed/NCBI
5	Molina G, Hull MA, Chen YL, DeLaney TF, De Amorim Bernstein K, Choy E, Cote G, Harmon DC, Mullen JT and Haynes AB: Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. J Surg Oncol. 114:814–820. 2016. View Article : Google Scholar : PubMed/NCBI
6	Mansfield SA, Pollock RE and Grignol VP: Surgery for abdominal well-differentiated liposarcoma. Curr Treat Options Oncol. 19:12018. View Article : Google Scholar : PubMed/NCBI
7	Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S and Wu A: Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 86:2226–2234. 2016. View Article : Google Scholar : PubMed/NCBI
8	Lin H, Zhang Q, Li X, Wu Y, Liu Y and Hu Y: Identification of key candidate genes and pathways in hepatitis B virus-associated acute liver failure by bioinformatical analysis. Medicine (Baltimore). 97:e96872018. View Article : Google Scholar : PubMed/NCBI
9	Guo Y, Bao Y, Ma M and Yang W: Identification of key candidate genes and pathways in colorectal cancer by integrated bioinformatical analysis. Int J Mol Sci. 18:7222017. View Article : Google Scholar
10	Lee S and Howell BJ: High-content screening: Emerging hardware and software technologies. Methods Enzymol. 414:468–483. 2006. View Article : Google Scholar : PubMed/NCBI
11	Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, et al: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 42:715–721. 2010. View Article : Google Scholar : PubMed/NCBI
12	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wettenhall JM and Smyth GK: limmaGUI: A graphical user interface for linear modeling of microarray data. Bioinformatics. 20:3705–3706. 2004. View Article : Google Scholar : PubMed/NCBI
14	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B (Methodological). 57:289–300. 1995. View Article : Google Scholar
15	Tang S, Jing H, Huang Z, Huang T, Lin S, Liao M and Zhou J: Identification of key candidate genes in neuropathic pain by integrated bioinformatic analysis. J Cell Biochem. 121:1635–1648. 2020. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Balboa-Beltrán E, Duran G, Lamas MJ, Carracedo A and Barros F: Long survival and severe toxicity under 5-fluorouracil-based therapy in a patient with colorectal cancer who harbors a germline codon-stop mutation in TYMS. Mayo Clin Proc. 90:1298–1303. 2015. View Article : Google Scholar : PubMed/NCBI
18	Lee SW, Chen TJ, Lin LC, Li CF, Chen LT, Hsing CH, Hsu HP, Tsai CJ, Huang HY and Shiue YL: Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. Exp Mol Pathol. 95:83–90. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL and Ho JC: Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol. 44:2093–2102. 2014. View Article : Google Scholar : PubMed/NCBI
20	Formentini A, Henne-Bruns D and Kornmann M: Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: A review. Langenbecks Arch Surg. 389:405–413. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lam SK, Li YY, Zheng CY and Ho JC: Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma. Int J Oncol. 46:113–122. 2015. View Article : Google Scholar : PubMed/NCBI
22	Burdelski C, Strauss C, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen M, et al: Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget. 6:8377–8387. 2015. View Article : Google Scholar : PubMed/NCBI
23	Abdallah EA, Fanelli MF, Buim ME, Machado Netto MC, Gasparini Junior JL, Souza E, Silva V, Dettino AL, Mingues NB, Romero JV, et al: Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. Int J Cancer. 137:1397–1405. 2015. View Article : Google Scholar : PubMed/NCBI
24	Ding B, Gao M, Li Z, Xu C, Fan S and He W: Expression of TYMS in lymph node metastasis from low-grade glioma. Oncol Lett. 10:1569–1574. 2015. View Article : Google Scholar : PubMed/NCBI
25	Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y and Itoh K: Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Clin Cancer Res. 10:5828–5836. 2004. View Article : Google Scholar : PubMed/NCBI
26	Mpindi JP, Sara H, Haapa-Paananen S, Kilpinen S, Pisto T, Bucher E, Ojala K, Iljin K, Vainio P, Björkman M, et al: GTI: A novel algorithm for identifying outlier gene expression profiles from integrated microarray datasets. PLoS One. 6:e172592011. View Article : Google Scholar : PubMed/NCBI
27	Abu Lila AS, Moriyoshi N, Fukushima M, Huang CL, Wada H and Ishida T: Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. Cancer Lett. 400:223–231. 2017. View Article : Google Scholar : PubMed/NCBI
28	Ide H, Kikuchi E, Hasegawa M, Hattori S, Yasumizu Y, Miyajima A and Oya M: Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer. Cancer Med. 2:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
29	Ligabue A, Marverti G, Liebl U and Myllykallio H: Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression. PLoS One. 7:e473182012. View Article : Google Scholar : PubMed/NCBI
30	Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, et al: Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 125:1759–1767. 2015. View Article : Google Scholar : PubMed/NCBI
31	Toh TB, Lim JJ, Hooi L, Rashid M and Chow EK: Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. 72:104–118. 2020. View Article : Google Scholar : PubMed/NCBI
32	Yang H, Ma P, Cao Y, Zhang M, Li L, Wei J, Tao L and Qian K: ECPIRM, a potential therapeutic agent for cutaneous T-cell lymphoma, inhibits cell proliferation and promotes apoptosis via a JAK/STAT pathway. Anticancer Agents Med Chem. 18:401–411. 2018. View Article : Google Scholar : PubMed/NCBI
33	Olbrich T, Mayor-Ruiz C, Vega-Sendino M, Gomez C, Ortega S, Ruiz S and Fernandez-Capetillo O: A p53-dependent response limits the viability of mammalian haploid cells. Proc Natl Acad Sci USA. 114:9367–9372. 2017. View Article : Google Scholar : PubMed/NCBI
34	Peng K, Li X, Wu C, Wang Y, Yu J, Zhang J, Gao Q, Zhang W, Zhang Q, Fan Y, et al: Derivation of haploid trophoblast stem cells via conversion in vitro. iScience. 11:508–518. 2019. View Article : Google Scholar : PubMed/NCBI
35	Li Y and Shuai L: A versatile genetic tool: Haploid cells. Stem Cell Res Ther. 8:1972017. View Article : Google Scholar : PubMed/NCBI
36	Fletcher CDM, Bridge JA, Hogendoorn P and Mertens F: World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. (4th). (Lyon). IARC Press. 2013.
37	Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F and Lagarde C: Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 33:37–42. 1984. View Article : Google Scholar : PubMed/NCBI